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Abstract
Incidence rates for renal cell cancer, which accounts for 85% of kidney cancers, have been rising more rapidly
among blacks than whites, almost entirely accounted for by an excess of localized disease. This excess dates back
to the 1970s, despite less access among blacks to imaging procedures in the past. In contrast, mortality rates for
this cancer have been virtually identical among blacks and whites since the early 1990s, despite the fact that
nephrectomy rates, regardless of stage, are lower among blacks than among whites. These observations suggest
that renal cell cancer may be a less aggressive tumor in blacks. We have reviewed the epidemiology of renal cell
cancer, with emphasis on factors which may potentially play a role in the observed differences in incidence and
mortality patterns of renal cell cancer among blacks and whites. To date, the factors most consistently, albeit
modestly, associated with increased renal cell cancer risk in epidemiologic studies among whites - obesity,
hypertension, cigarette smoking - likely account for less than half of these cancers, and there is virtually no
epidemiologic evidence in the literature pertaining to their association with renal cell cancer among blacks. There
is a long overdue need for detailed etiologic cohort and case-control studies of renal cell cancer among blacks, as
they now represent the population at highest risk in the United States. In particular, investigation of the influence
on renal cell cancer development of hypertension and chronic kidney disease, both of which occur substantially
more frequently among blacks, is warranted, as well as investigations into the biology and natural history of this
cancer among blacks.
Background
An estimated 58,240 new cases of kidney cancer and
13,040 deaths are expected in the United States in 2010,
accounting for approximately 4% of all new primary
cancer cases diagnosed [1]. Approximately 85% of kid-
ney cancers are renal parenchyma (renal cell) cancers,
while the remainder are mainly urothelial cancers of the
renal pelvis [1]. Both renal cell and renal pelvis cancers
are about twice as common among men as among
women [1,2], with the mean age at diagnosis in the
early 60s for renal cell cancer and in the late 60s for
renal pelvis cancer. Epidemiologic characteristics and
risk factors for renal pelvis cancer closely parallel for
those for bladder cancer and have been addressed by
the authors elsewhere [3].
Over the past several decades, incidence rates for renal
cell cancer have been rising steadily each year in the
United States [4]. Improved imaging technology has led
to earlier detection and a decrease in the size of diag-
nosed renal cell tumors over time [5,6], but an increase
in the incidence of large and late-stage renal cell cancers
has also been observed [4,6,7]. A recent report showed
that, while the rate for all cancers combined dropped
1.8% among men and 0.5% among women in the United
States between 2001 and 2005, kidney cancer incidence
is rising 1.7% per year for males and 2.2% per year for
females [8].
Perhaps the most prominent feature of the descriptive
epidemiology of renal cell cancer has been the more rapid
increase in incidence among blacks than whites, leading to
a shift in excess from among whites to among blacks
beginning in the mid-1980s [7] (Figure 1). By 2002-2007,
the age-adjusted incidence rates of renal cell cancer
among black men, white men, black women, and white
women were 20.0, 17.4, 9.6 and 8.8 per 100,000 person-
years, respectively [2]. The higher incidence of renal cell
cancer among blacks is almost entirely accounted for by
an excess of localized disease among patients of all ages
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the 1970s [9,10]; for the periods 1973-77, 1978-82 and
1983-87, the incidence rates (per 100,000) for localized
renal cell cancer were 3.7, 4.7 and 6.1 for black men, 3.5,
3.9, and 5.0 for white men, 1.8, 2.2 and 2.8 for black
women, and 1.7, 1.8 and 2.3 for white women, respectively.
Localized renal cell cancer has also been increasing at a
significantly faster pace among blacks of all ages than
among whites since the 1970s [10].
Early stage renal cell cancer is typically detected inci-
dentally by imaging modalities which, on the basis of
socioeconomic factors and accessibility to medical care,
a r eu n l i k e l yt ob eu t i l i z e dm o r ef r e q u e n t l yb yb l a c k s
than whites [10,11]. Viewed historically, access to ima-
ging and other medical technologies was not as available
to blacks as it was to whites 30 to 40 years ago when
the accelerated increase in the incidence of localized dis-
ease began among blacks. It is possible that the diagnos-
tic work-up for co-morbidities more common among
blacks may yield incidental findings of localized renal
cell tumors. Presently, the higher prevalence of advanced
chronic kidney disease among blacks [12] may result in
increased renal surveillance with a concomitant
increased detection of early renal tumors; but the most
common co-morbidities among blacks, hypertension
and diabetes, are not generally associated with increased
imaging. Thus, the observed differences between blacks
and whites in early stage renal cell tumor distribution
dating back to the 1970s is unlikely to be a result of
long-term greater access to and utilization of imaging
technologies by blacks.
In contrast to these incidence trends, United States
kidney cancer mortality rates, which include renal pelvis
cancer but primarily reflect patterns related to renal cell
cancer, have been virtually identical among blacks and
whites for both men and women since the early 1990s
(Figure 2). This equivalence in mortality despite higher
incidence does not appear to be a result of higher rates
of nephrectomies among blacks [9]; rates of nephrect-
omy are in fact lower among blacks than among whites,
while cause-specific survival is comparable or higher
among blacks.
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Figure 1 Trends in age-adjusted (2000 United States standard) incidence of renal cell cancer by race and sex, 1974-2007 (Based on
SEER data for nine geographic regions of the United States: Atlanta, Georgia; Connecticut; Detroit, Michigan; Hawaii; Iowa; New
Mexico; San Francisco/Oakland, California; Seattle/Puget Sound, Washington; and Utah) [2].
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that the biology of renal cell cancer may differ between
blacks and whites. In particular, renal cell cancer may
be a less aggressive tumor among blacks [9], as sug-
gested by the favorable stage distribution among blacks
and their higher survival, particularly for distant and
unstaged cancer. Zini et al. [13] have also reported simi-
lar survival despite lower nephrectomy rates among
blacks, although others have reported lower survival
rates among blacks compared with whites with renal
cell cancer [14,15].
Methods
We have conducted a review of epidemiologic studies of
risk factors for renal cell cancer, identified through a
PubMed search of the literature. For the purposes of
this review, all papers published through 2010 were
initially identified by use of either the term “renal can-
cer” or the term “kidney cancer” together with the term
“risk factor” or “epidemiology.” Moreover, all review
papers addressing risk factors for kidney cancer in gen-
eral or renal cell cancer in particular were identified,
and references were examined to supplement, if neces-
sary, papers identified through the initial search.
A qualitative evaluation and summary of the results of
i n d i v i d u a ls t u d i e si sp r e s e n t e d ;r a t h e rt h a nc i t i n ge v e r y
paper we have identified, we have chosen to emphasize
those results that reflect consistency in the literature
and, more importantly, that may potentially play a role
in the observed differences in incidence and mortality
patterns of renal cell cancer among blacks and whites.
No consistent association has been demonstrated
between renal cell cancer and social class variables such
as education or income. Despite considerable racial dif-
ferences in the descriptive epidemiology of this malig-
nancy, there have been virtually no etiologic
epidemiologic studies presenting results for lifestyle and
other risk factors for renal cell cancer separately among
blacks, and even the small number of multiethnic stu-
dies conducted to date have generally not presented
results separately for blacks and whites [16-20], often
because of small numbers of blacks in the study
population.
Results and Discussion
Genetic susceptibility
Renal cell cancer occurs in both hereditary and sporadic
forms. Hereditary renal cell cancer tends to occur earlier
in life than sporadic forms of the disease, and often
involves bilateral, multifocal tumors [21]. Having a first
degree relative with kidney cancer has been associated
with a 2- to 5-fold increased risk [22]. A recent meta-
analysis suggested that the observed risk is higher when
the affected relative is a sibling rather than a parent,
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Figure 2 Trends in age-adjusted (2000 United States standard) mortality from kidney cancer by race and sex, 1971-2007 (Based on
National Center for Health Statistics data for the entire United States) [2].
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Page 3 of 11supporting the role of recessive, low-penetrance genes in
familial renal cell cancer [22,23]. In a case-control study
that evaluated whites and blacks separately and relied
on self-reported family history of kidney cancer, the
relative risk for renal cell cancer associated with a family
history of kidney cancer was higher, although not statis-
tically significantly so, among blacks than among whites
[24]; for any first-degree relative with kidney cancer, the
relative risk for renal cell cancer was 3.96 (95% CI 1.45-
10.84) among blacks and 1.98 (95% CI 0.99-4.03) among
whites.
Although fewer than 5% of renal cell cancers are
explained by inherited predisposition [21,25], no other
cancer has as many different types of genetic predispo-
sition as renal cell cancer [26]. Renal medullary cancer
is a rare, usually fatal primary kidney tumor that
afflicts almost exclusively young blacks with sickle cell
trait or disease [27]. The tumor, which displays unique
clinical and pathological characteristics, originates
from the epithelium of renal collecting ducts, and is
almost always metastatic at the time of diagnosis, with
death usually occurring within a few months of diag-
nosis. This highly aggressive tumor was first described
in 1995 [28], and approximately 120 cases have been
reported to date, virtually all among patients aged less
than 40 years [29].
Other rare genetic forms of renal cell cancer are von
Hippel-Lindau (VHL) disease (predisposing to clear cell
cancer), hereditary papillary renal cell carcinoma
(HPRC), hereditary leiomyomatosis renal cell cancer
(papillary), Birt-Hogg-Dubé syndrome (mainly chromo-
phobe and oncocytoma), chromosome 3 translocation-
associated (clear cell), tuberous sclerosis (clear cell),
mutated succinate dehydrogenase genes, and Cowden
syndrome [21,25,30]. Genes have been identified related
to these inherited forms of renal cell cancer: the tumor
suppressor VHL gene located on the distal region of
chromosome 3p [31], the EPAS-1 gene encoding the
HIF-2a transcription factor that is critical in kidney car-
cinogenesis for VHL-deficient RCC [32], six different
rare germline translocations affecting chromosome 3 in
a small number of families with familial clear cell renal
cancer [33-35], the MET gene for hereditary papillary
carcinoma, the FLCN gene for Birt-Hogg-Dubé syn-
drome, the FH gene for hereditary leiomyomatosis renal
cell cancer, three succinate dehydrogenase genes includ-
ing SDHB [36], and the tumor suppressor phosphatase
and tensin homolog (PTEN)a n dKILLIN genes in Cow-
den syndrome [37]. All of the identified genes are
involved in pathways that respond to metabolic stress or
nutrient stimulation [36]. Aside from the sickle cell trait,
none of the inherited syndromes associated with
increased risk of kidney cancer has been reported to
have a higher prevalence in blacks.
Chronic kidney disease
It is well-established that patients on renal replacement
therapy for end stage chronic kidney disease are at
increased risk for many cancers [38]. In particular, sev-
eral large studies conducted in North America, Europe,
or Australia and New Zealand have reported substan-
tially elevated relative risks for renal cell cancer among
patients on dialysis or renal transplantation therapy for
end-stage kidney disease, independent of underlying pri-
mary renal disease, with relative risks ranging from 3.3
up to almost 15 [39-44]. The risk for renal cell cancer
rises with duration of dialysis treatment [44]. Acquired
renal cystic disease of the native kidneys, which occurs
among dialysis patients independent of age or primary
renal disease and whose prevalence also increases with
duration of dialysis, is believed to account for the excess
of renal cell carcinoma among patients on dialysis
[44,45]. The increased cancer risk among transplant
recipients is likely due, at least in part, to the use of
immune-suppressing medications [38]. Evidence for an
association between early stage chronic kidney disease
and renal cell cancer risk is more limited [42,46].
Rates of end stage renal disease, in particular hyperten-
sion- and diabetes- related end stage renal disease, are
consistently reported to be at least four-fold higher
among blacks than among whites [47-49]. The rate of
hypertension-related end stage renal disease is 20 times
higher among 20 to 44 year old black males compared
with their white counterparts [48]. In contrast, rates of
earlier stage chronic kidney disease are similar or
increased among whites compared with blacks [12,50,51].
Between 1999 and 2004, the prevalence of all stages of
chronic kidney disease combined, defined by a combina-
tion of glomerular filtration rate (GFR) < 60 ml/min/1.73
m
2 and high proteinuria, was reported to be 16.1%
among whites and 19.9% among blacks [52]. Detailed
analyses based on GFR measurements have demonstrated
a white excess for mild chronic kidney disease giving way
to a black excess for moderate to severe chronic kidney
disease [52,53]. For example, in the Reasons for Geo-
graphic And Racial Differences in Stroke (REGARDS)
cohort study, the black:white odds ratio for impaired kid-
ney function was 0.74 (95% CI 0.66-0.84) among indivi-
duals with a GFR between 50 and 59 ml/min/1.73 m
2,
increasing to 2.96 (95% CI 1.72-5.11) among those with a
GFR between 10 and 19 ml/min/1.73 m
2 [53]. It has also
been suggested that a lower level of blood pressure may
be necessary to slow the decline in renal function among
blacks with chronic kidney disease and hypertension
compared with whites [54,55], but racial differences in
the susceptibility to renal damage from elevated blood
pressure have been reported to persist even after adjust-
ment for differences between blacks and whites in hyper-
tension and hypertension-control [56].
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Page 4 of 11A recent study [57] showed that, among blacks, focal
segmental glomerulosclerosis and hypertension-attribu-
ted end-stage kidney disease are strongly associated with
variants in the APOL1 gene on chromosome 22, sup-
porting a genetic basis for predisposition to kidney dis-
ease in blacks. The APOL1 risk alleles for renal disease
occur in more than 30% of African-American chromo-
somes but appear to be absent in whites [57], and it is
possible that a similar genetic marker associated with
renal cell cancer may exist among blacks.
Obesity
Regardless of study design, renal cell cancer is consis-
tently associated with obesity. The association of renal
cell carcinoma with obesity has been reported in vir-
tually all epidemiologic studies, including many large
prospective studies conducted in various populations,
and most studies have observed an effect of elevated
BMI among both men and women. Only one large
cohort study of 3,668,486 white and 832,214 black male
US veterans has specifically evaluated obesity-related
renal cell cancer risk separately among blacks, but it
used a hospital diagnosis of obesity rather than BMI as
t h em e a s u r eo fe x p o s u r e[ 5 8 ] .T h er e l a t i v er i s k sf o r
renal cell cancer associated with clinical obesity were
1.74 (95% CI 1.58-1.90) among white men and 1.38
(95% CI 1.09-1.74) among black men. Risk for renal cell
cancer was significantly elevated among white men with
or without hypertension, while among black men risk of
renal cell cancer was not elevated among those without
hypertension [58]. In a large, Swedish population-based
study that used measurements of height and weight
rather than questionnaire-derived data, the relative risks
for renal cell cancer associated with being overweight
(BMI 25.0-29.9) or obese (BMI > 30) were 1.28 and
1.82, respectively [59].
Recent quantitative summary analyses of the epide-
miologic evidence reported that associations with
increased BMI were slightly stronger in women than in
men [60-62]; Renehan et al. presented summary risk
ratios of 1.24 (95% CI 1.15-1.34) among men and 1.34
(95% CI 1.25-1.43) among women per 5 kg/m
2 increase
in BMI [62], while pooled relative risks from cohort stu-
dies were 1.06 among women and 1.05 among men per
unit increase in BMI [60,61].
The rising incidence of renal cell cancer is likely to be
accounted for in part by the increasing prevalence of
obesity [63,64], although increases in obesity prevalence
observed since the 1980s may not be continuing at the
same rate in recent years, particularly among white men
[62]. In 2007-2008 in the United States, the prevalence
of obesity (BMI ≥ 30) and of obesity and overweight
combined (BMI ≥ 25) were 33.8% and 68%, respectively
[62]. The prevalence of obesity in the United States is
up to 50% higher among blacks when compared with
whites, with the difference more pronounced among
women than men [62,63]. The proportion of renal cell
cancer attributable to being overweight and obese could
be as high as 40% in the United States and Canada
[64-66].
Several credible mechanisms have been suggested for
the association between obesity and renal cell cancer.
Obesity regulates the release of free fatty acids and adi-
pose tissue-derived hormones and cytokines, including
leptin and adiponectin [34]. While levels of most cyto-
kines, including leptin, are increased in obese indivi-
duals, serum adiponectin levels are inversely correlated
with BMI among both blacks and whites [67-69], and
appear to be lower in blacks compared with whites
[67,69-74]. A few small studies have shown reduced adi-
ponectin levels in patients with renal cell cancer, and an
inverse correlation between adiponectin levels and mar-
kers of tumor aggressiveness, including tumor size and
metastasis [75-77]. Moreover, circulating levels of adipo-
nectin are inversely associated with insulin resistance,
and elevated circulating insulin levels and increases in
the bioavailability of insulin-like growth factor-I (IGF-I)
associated with obesity could in turn lead to increased
cell proliferation and the development of renal cell can-
cer [78-80]. A recent study showed that, while BMI was
associated with IGF-1 levels regardless of race, black
women had higher mean IGF-1 levels compared with
white women adjusted for BMI. Lipid peroxidation of
proximal renal tubules, which is increased among obese
subjects, has also been hypothesized to play a role in the
association of obesity with renal cell cancer through the
formation of DNA adducts [81].
Hypertension
While it is difficult to separate the effects of hyperten-
sion or its treatment on renal cell cancer risk, as they
are highly correlated variables, the collective epidemiolo-
gic evidence to date suggests that it is hypertension itself
that plays a role in the etiology of this tumor. There
appears to be no excess risk for renal cell cancer asso-
ciated with use of any type of class of antihypertensive
medications or with diuretic use, after adjustment for
high blood pressure [82-86]. Most studies have reported
relative risks for renal cell cancer associated with either
recorded blood pressure or reported hypertension ran-
ging between 1.2 and 2 or greater, and several cohort
studies have demonstrated an increased risk even after
exclusion of the first few years of follow-up, when early
stage, prediagnostic renal tumors may themselves lead
to elevated blood pressure [20,82-84,87,88].
Trends of increasing renal cell cancer incidence may
be associated with the increasing prevalence of hyper-
tension in the United States [89-91], particularly among
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Page 5 of 11blacks. While awareness and treatment of hypertension
has improved among blacks over time, a substantially
higher prevalence of hypertension among blacks com-
pared with whites persists, as does the large difference
between blacks and whites in the proportion of patients
with hypertension who are receiving treatment [91,92].
The diagnostic work-up for hypertension, while more
common among blacks, is not generally associated with
increased imaging, so hypertension is unlikely to
account for the more common occurrence of incidental
localized renal cell tumors among blacks compared with
whites. In fact, detection bias due to incidental diagnosis
during work-ups for hypertension was not supported in
a study which directly evaluated that hypothesis [93].
Although the effect of hypertension on renal cell cancer
is believed to be independent of obesity, adiponectin
levels are lower among blacks than among whites, and
low adiponectin levels have been linked in a few studies
to hypertension as well as obesity. Moreover, despite the
linear relationship between increased body weight and
increased blood pressure in whites, it has been sug-
gested that blacks have higher blood pressures at lower
weights compared with whites [94].
Several biologic mechanisms for the association
between high blood pressure and renal cell cancer risk
have been proposed, including hypertension-induced
renal injury or metabolic or functional changes within
the renal tubule induced by hypertension increasing sus-
ceptibility to carcinogens. It has also been speculated
that elevated levels of insulin-like growth factor-I (IGF-
I) or lipid peroxidation associated with hypertension, as
well as up-regulation of hypoxia-inducible factors, could
contribute to the development of renal cell cancer.
Cigarette smoking
Cigarette smoking is a recognized though moderate
cause of renal cell cancer [95]. A meta-analysis [96] of
data from 19 case-control studies (8,032 cases and
13,800 controls) and 5 cohort studies (1,457,754 parti-
cipants with 1,326 renal cell cancer cases) reported sta-
tistically significant relative risks of 1.5 and 1.2 for
male and female smokers, respectively. There was a
strong dose-dependent increase in risk, up to 2- and
1.6-fold among heavy (21 or more cigarettes per day)
men and women smokers, respectively. There was a
significant decline in risk in both sexes with years of
cessation, with a 15 to 30% reduction in risk 10 to 15
years after quitting [96]. Approximately 20 to 30% of
renal cell cancers among men and 10 to 20% among
women are estimated to be attributable to cigarette
smoking [89,97,98]. According to the 1998 Surgeon
General’s report on tobacco use, the prevalence of
smoking declined among African Americans between
1978 and 1995, from 37.3% to 26.5% overall, and while
blacks have higher rates of smoking they are less likely
than whites to be heavy smokers and smoke fewer
cigarettes per day, so this causal factor is an unlikely
explanation for the excess incidence of renal cell can-
cer among blacks [99].
Statins
Statins are widely used drugs for the treatment of lipid
disorders, particularly hypercholesterolemia. Anti-
tumorigenic properties of statins have been documented,
including their inhibition of proliferation and promotion
of apoptosis, but their potential effectiveness for the pri-
mary prevention of cancer has not been conclusively
demonstrated. Despite observed differences between
blacks and whites in both the prevalence of hypercholes-
terolemia and its treatment with statins, both lower
among blacks than whites [100,101], to our knowledge
no study has evaluated the association between statin
use and renal cell cancer among blacks.
Other lifestyle factors
Several other factors have been extensively evaluated in
epidemiologic studies of renal cell cancer. However,
credible or consistent associations of these factors with
renal cell cancer have not been reported, and they do
not play an obvious role in explaining the unusual pat-
terns of renal cell cancer incidence and mortality among
blacks and whites. The collective epidemiologic evidence
related to these characteristics and risk factors has been
addressed by the authors in detail elsewhere [102,103]
and, therefore, will be mentioned here only in brief.
Analgesics
Historically, the causal connection of heavy use and
abuse of phenacetin-containing analgesics and transi-
tional cell cancers of the renal pelvis has long been
recognized [3]. Phenacetin’s effect on adenocarcinomas
of the renal parenchyma, however, is inconclusive, and
it is now impossible to assess because phenacetin-con-
taining analgesics have been off the market for up to 30
years in most countries and reliable recall of past intake
is no longer achievable. Neither acetaminophen, the
major metabolite of phenacetin, nor aspirin has been
credibly associated with an increase in renal cell cancer
risk. To date, there is no epidemiologic investigation of
analgesic use and renal cell cancer among blacks.
Diet
Although originally thought almost 40 years ago to play
a key role in renal cell cancer etiology, dietary factors
have not fulfilled their early promise, as renal cell cancer
has not been convincingly linked to any specific dietary
factor. To our knowledge, there has been no etiologic
study of renal cell cancer and diet to publish results spe-
cifically among blacks. A protective effect for overall
fruit and vegetable consumption has been generally
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based on 375,851 participants in the European Prospec-
tive Investigation into Cancer And Nutrition (EPIC)
[104] and the other based on 120,852 men and women
in the Netherlands cohort study on diet and cancer
(NLCS) [105], reported no protective effect of vegetable
and/or fruit consumption on renal cell cancer. Some
epidemiologic studies suggest that elevated protein con-
sumption may be a risk factor for renal cell cancer.
There may be some biologic plausibility to a high pro-
tein diet affecting risk of renal cell cancer, because ani-
mal studies have shown protein intake can induce renal
tubular hypertrophy, but the large international renal
cell cancer case-control study failed to provide clear
support for this hypothesis [106], as did a large, pooled
analysis of 13 cohort studies [107].
Alcohol consumption
Early ecologic studies consistently suggested a positive
correlation between kidney cancer and per capita con-
sumption of alcohol, but these ecologic findings were
not confirmed by numerous analytic epidemiologic stu-
dies of renal cell cancer conducted during the ensuing
two decades [100,101]. After adjustment for the con-
founding effect of cigarette use, virtually all studies,
including cohort studies of alcoholics and brewery
workers, showed no association between alcohol con-
sumption and renal cell cancer.
By contrast, a post hoc hypothesis has recently appeared
in the literature that moderate levels of alcohol consump-
tion may be protective for renal cell cancer. The findings
of recent individual studies show considerable heterogene-
ity and inconsistency with respect to the categories of
alcohol consumption, the amount of alcohol intake report-
edly associated with decreased renal cell cancer risk, and
differential observations between men and women. A
pooled analysis of data from 12 prospective studies of
renal cell cancer was recently published, based on results
of five published studies as well as numerous others which
had not previously published their data related to alcohol
consumption [108]. The pooled analysis was based on
1430 incident cases of renal cell cancer (719 men and 711
women), and demonstrated an apparent inverse-response
relation at levels of consumption equivalent to less than a
drink per day, with no further protective effect at levels of
intake above a drink a day. It is difficult to imagine the
biologic mechanism that could explain this unusual type
of dose-response pattern. Unless of course one invokes a
hormesis-like effect of low-dose alcohol on renal cancer
risk while other body organs apparently do not enjoy this
low-dose anti-carcinogenic effect.
Finally, alcohol itself is a known human carcinogen
and heavy alcohol drinking has been conclusively linked
to increased risks of numerous types of cancer, includ-
ing oral, pharyngeal, laryngeal, esophageal, liver and
probably breast and colon and rectum [109]. A protec-
tive effect of alcohol consumption on renal cell cancer
at very low levels of intake has little biologic plausibility
or credibility. In addition to the extensive analytic epide-
miologic evidence from the past 40 years, the descriptive
patterns of renal cell cancer are not consistent with an
inverse association with alcohol intake. In particular, the
rate of renal cell cancer among men is twice that among
women worldwide, whereas men tend to consume alco-
hol at substantially higher levels than women.
Hormonal and reproductive factors
Reductions in risk of renal cell cancer have been
reported among users of oral contraceptives in some
[110,111] but not all studies [112,113], and in the large
international case-control study protection was
restricted to non-smokers [110]. Hormones have
induced renal tumors in laboratory animals; however,
with the exception of an almost two-fold increased risk
among women with high parity compared with nullipar-
ous women in some studies, after adjustment for obesity
[110,111,114], evidence for a role of hormonal or repro-
ductive factors in the etiology of renal cell cancer in
humans is not strong or consistent.
Occupation
As compared with bladder cancer, renal cell cancer has
not been convincingly linked to any occupational expo-
sure. However, because of the large number of epide-
miologic studies of this cancer, particularly case-control
studies, that have been conducted over the last three
decades, a number of sporadic associations have been
reported between exposures or jobs/industries and renal
cell cancer. Most attention has been focused on asbes-
tos, gasoline and, more recently, the solvent trichlor-
oethylene (TCE). Extensive reviews and meta-analyses of
occupational cohort studies have failed to confirm suspi-
cions of increased risk of kidney cancer among workers
exposed to asbestos or gasoline [115-117].
Three epidemiologic studies conducted in one area of
Germany, which were initiated in response to a cluster
of renal cell cancer cases observed in a plant, reported
strikingly elevated relative risks for renal cell cancer
associated with TCE exposure [118-120]. The findings
contrast starkly with results from other investigations,
and several serious methodological shortcomings of
these studies have been noted [121-123] limiting any
conclusion that can be drawn. To date, seven occupa-
tional cohort studies have evaluated the relationship
between TCE exposure and specific types of cancer. The
two largest, which both employed sophisticated methods
of exposure assessment and internal and external com-
parisons [124,125], reported no significantly increased
risk of renal cell cancer among TCE exposed workers.
The most recent cohort study [126], conducted in
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workers with presumed TCE exposure and found a
weak association with renal cell cancer among those
t h o u g h tt ob eh e a v i l ye x p o s e dt oT C E .T h ew e i g h to f
the evidence to date, however, does not provide consis-
tent, credible support for the hypothesis that TCE is a
cause of renal cell cancer in humans [127]. Whether
TCE is a renal carcinogen in humans remains an open
question, which will require more and better research.
Conclusions
To date, the factors most consistently associated with
increased renal cell cancer risk in epidemiologic studies -
obesity, hypertension, cigarette smoking - likely account
for less than half of these cancers among whites, and
there is scant published evidence pertaining to their asso-
ciation among blacks with renal cell cancer. In light of
the enigmatic differences in incidence and mortality
trends in renal cell cancer among blacks, there is an
urgent need for detailed etiologic cohort and case-control
studies of renal cell cancer among blacks, as they now
represent the population at highest risk in the United
States. In particular, detailed investigations are needed of
the influence on renal cell cancer development of hyper-
tension and chronic kidney disease, both of which occur
much more commonly among blacks, as well as investi-
gations of genetic markers which may reflect greater sus-
ceptibility to renal cell cancer among blacks. Further,
detailed studies of the biology and natural history of
renal cell cancer among blacks are essential.
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